April 2020 in “Trends in Immunotherapy” Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.
October 2011 in “Reactions Weekly” A man had a severe allergic reaction to sulfasalazine, with symptoms improving after treatment and follow-up.
January 2026 in “Journal of Clinical Medicine” Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.
December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
14 citations
,
January 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
2 citations
,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
October 2023 in “International journal of rheumatic diseases” New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
2 citations
,
November 2007 in “Clinics in dermatology” Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
July 2025 in “Pharmaceutics” Recombinant Human Annexin A5 may help treat localized scleroderma by reducing skin thickening and inflammation.
January 2024 in “Dermatologic Therapy” Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
Baricitinib may not always prevent relapse in alopecia areata.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
52 citations
,
December 2014 in “Journal of Dermatological Science” Apremilast may help treat hair loss in alopecia areata.
6 citations
,
March 2016 in “Scandinavian journal of immunology” Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
22 citations
,
May 2017 in “Journal of dermatological treatment” BD 1/4 dilution is the best for treating localized alopecia areata in adults.
1 citations
,
December 2022 in “The Nishinihon Journal of Dermatology” Baricitinib is an effective treatment for severe alopecia areata.
January 2024 in “Journal der Deutschen Dermatologischen Gesellschaft” Non-biologic immunosuppressive drugs are crucial for treating autoimmune and chronic inflammatory skin diseases.
May 2024 in “Frontiers in Medicine” Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.
January 2002 in “대한피부과학회지” Most patients with dermatomyositis had skin rash and were treated with prednisolone and hydroxychloroquine.
A 44-year-old woman with Down's syndrome was diagnosed with both rheumatoid and gouty arthritis and treated with multiple medications.
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
December 2023 in “Journal of health and rehabilitation research” Oral Apremilast effectively treats alopecia areata in most patients.
February 2026 in “Frontiers in Medicine” Topical immunotherapy is still effective for managing alopecia areata, even with new treatments available.
November 2025 in “Journal of Investigative Dermatology” Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.
June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
July 2003 in “Journal of Cutaneous Medicine and Surgery” Some medications can improve skin conditions, while lifestyle factors like smoking and drinking may worsen them; treatments like monoclonal antibodies and imiquimod cream show promise for certain skin diseases.